The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1107
Pegylated Interferon (PEG-Intron) for Chronic Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pegylated Interferon (PEG-Intron) for Chronic Hepatitis C
Recombinant interferon alfa-2b conjugated to polyethylene glycol (PEG-Intron), the first "pegylated"alpha interferon, has been approved by the FDA for once-a-week monotherapy of chronic hepatitis C virus (HCV) infection in patients not previously...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegylated Interferon (PEG-Intron) for Chronic Hepatitis C
Article code: 1107b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.